4 cytundeb, rhan amser, yn gyfan gwbl o bell, swydd yn Cambridge
Hyderus o ran Anabledd
Gweithio o bell
Lleoliad
- UK
- Eastern England
- Cambridgeshire
- Cambridge (4)
- Cambourne (1)
- Chesterton (1)
- Girton (1)
- Sawston (1)
Dyddiad hysbysebu
Categori
Math o gytundeb
Oriau
Mewngofnodwch nawr i greu rhybudd e-bost a derbyn y swyddi diweddaraf ar gyfer y chwiliad hon yn syth i'ch e-bost
MewngofnodiElderly Befriender
- 08 June 2024
- Home Instead - Sawston, Cambridge
- £13.25 to £14.85 per hour
- Yn gyfan gwbl o bell
- Cytundeb
- Rhan amser
Job description Elderly Befriender - Drivers needed. Care to Drink Tea and Eat Cake £14.85 per hour, guaranteed hours Availability to work Monday to Friday and alternate weekends (£14.85 earned wage including holiday pay) Home Instead Cambridge is expanding ...
Elderly Befriender
- 08 June 2024
- Home Instead - Cambourne, Cambridge
- £13.25 to £14.85 per hour
- Yn gyfan gwbl o bell
- Cytundeb
- Rhan amser
Job description Elderly Befriender - Drivers needed. Care to Drink Tea and Eat Cake £14.85 per hour, guaranteed hours Availability to work Monday to Friday and alternate weekends (£14.85 earned wage including holiday pay) Home Instead Cambridge is expanding ...
Elderly Befriender
- 08 June 2024
- Home Instead - Girton, Cambridge
- £13.25 to £14.85 per hour
- Yn gyfan gwbl o bell
- Cytundeb
- Rhan amser
Job description Elderly Befriender - Drivers needed. Care to Drink Tea and Eat Cake £14.85 per hour, guaranteed hours Availability to work Monday to Friday and alternate weekends (£14.85 earned wage including holiday pay) Home Instead Cambridge is expanding ...
Fractional CSO/Advisor - mRNA biotech
- 03 June 2024
- Hays Specialist Recruitment - Cambridge, Cambridgeshire, CB2 0AA
- £2,000.0 to £2,400.0 per day
- £200-300 per hour
- Yn gyfan gwbl o bell
- Cytundeb
- Rhan amser
Your new company You will be joining a breakthrough VC backed biotech who have recently raised a multi-million pound Seed funding round.They are pioneering novel treatments in the field of cancer immunoprevention and are currently developing a lead mRNA ...
- 1